S&P 500   4,536.19 (+0.37%)
DOW   35,609.34 (+0.43%)
QQQ   374.57 (-0.24%)
AAPL   149.23 (+0.32%)
MSFT   306.89 (-0.43%)
FB   340.32 (+0.10%)
GOOGL   2,836.96 (-0.97%)
TSLA   865.74 (+0.17%)
AMZN   3,416.85 (-0.79%)
NVDA   220.72 (-0.98%)
BABA   177.26 (+0.15%)
NIO   39.72 (-0.77%)
CGC   14.15 (-1.32%)
GE   105.89 (+1.11%)
AMD   116.28 (-0.04%)
MU   68.21 (+0.95%)
T   25.94 (+1.37%)
F   16.07 (+4.22%)
ACB   7.65 (+2.68%)
DIS   170.37 (-0.47%)
PFE   42.77 (+1.62%)
BA   215.96 (+0.00%)
AMC   40.90 (+0.25%)
S&P 500   4,536.19 (+0.37%)
DOW   35,609.34 (+0.43%)
QQQ   374.57 (-0.24%)
AAPL   149.23 (+0.32%)
MSFT   306.89 (-0.43%)
FB   340.32 (+0.10%)
GOOGL   2,836.96 (-0.97%)
TSLA   865.74 (+0.17%)
AMZN   3,416.85 (-0.79%)
NVDA   220.72 (-0.98%)
BABA   177.26 (+0.15%)
NIO   39.72 (-0.77%)
CGC   14.15 (-1.32%)
GE   105.89 (+1.11%)
AMD   116.28 (-0.04%)
MU   68.21 (+0.95%)
T   25.94 (+1.37%)
F   16.07 (+4.22%)
ACB   7.65 (+2.68%)
DIS   170.37 (-0.47%)
PFE   42.77 (+1.62%)
BA   215.96 (+0.00%)
AMC   40.90 (+0.25%)
S&P 500   4,536.19 (+0.37%)
DOW   35,609.34 (+0.43%)
QQQ   374.57 (-0.24%)
AAPL   149.23 (+0.32%)
MSFT   306.89 (-0.43%)
FB   340.32 (+0.10%)
GOOGL   2,836.96 (-0.97%)
TSLA   865.74 (+0.17%)
AMZN   3,416.85 (-0.79%)
NVDA   220.72 (-0.98%)
BABA   177.26 (+0.15%)
NIO   39.72 (-0.77%)
CGC   14.15 (-1.32%)
GE   105.89 (+1.11%)
AMD   116.28 (-0.04%)
MU   68.21 (+0.95%)
T   25.94 (+1.37%)
F   16.07 (+4.22%)
ACB   7.65 (+2.68%)
DIS   170.37 (-0.47%)
PFE   42.77 (+1.62%)
BA   215.96 (+0.00%)
AMC   40.90 (+0.25%)
S&P 500   4,536.19 (+0.37%)
DOW   35,609.34 (+0.43%)
QQQ   374.57 (-0.24%)
AAPL   149.23 (+0.32%)
MSFT   306.89 (-0.43%)
FB   340.32 (+0.10%)
GOOGL   2,836.96 (-0.97%)
TSLA   865.74 (+0.17%)
AMZN   3,416.85 (-0.79%)
NVDA   220.72 (-0.98%)
BABA   177.26 (+0.15%)
NIO   39.72 (-0.77%)
CGC   14.15 (-1.32%)
GE   105.89 (+1.11%)
AMD   116.28 (-0.04%)
MU   68.21 (+0.95%)
T   25.94 (+1.37%)
F   16.07 (+4.22%)
ACB   7.65 (+2.68%)
DIS   170.37 (-0.47%)
PFE   42.77 (+1.62%)
BA   215.96 (+0.00%)
AMC   40.90 (+0.25%)
NASDAQ:AQST

Aquestive Therapeutics Stock Forecast, Price & News

$4.38
+0.14 (+3.30 %)
(As of 10/20/2021 03:58 PM ET)
Add
Compare
Today's Range
$4.19
$4.59
50-Day Range
$3.62
$4.66
52-Week Range
$3.10
$8.06
Volume25,969 shs
Average Volume667,285 shs
Market Capitalization$170.32 million
P/E RatioN/A
Dividend YieldN/A
Beta3.53
30 days | 90 days | 365 days | Advanced Chart
Receive AQST News and Ratings via Email

Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Aquestive Therapeutics logo

About Aquestive Therapeutics

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients' therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AQST
Employees
187
Year Founded
N/A

Sales & Book Value

Annual Sales
$45.85 million
Book Value
($1.40) per share

Profitability

Net Income
$-55.78 million
Net Margins
-152.73%

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$170.32 million
Next Earnings Date
11/2/2021 (Confirmed)
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.90 out of 5 stars

Medical Sector

687th out of 1,360 stocks

Pharmaceutical Preparations Industry

326th out of 667 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












Aquestive Therapeutics (NASDAQ:AQST) Frequently Asked Questions

Is Aquestive Therapeutics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aquestive Therapeutics stock.
View analyst ratings for Aquestive Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Aquestive Therapeutics?

Wall Street analysts have given Aquestive Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aquestive Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Aquestive Therapeutics?

Aquestive Therapeutics saw a drop in short interest in August. As of August 31st, there was short interest totaling 1,570,000 shares, a drop of 23.0% from the August 15th total of 2,040,000 shares. Based on an average daily trading volume, of 575,800 shares, the days-to-cover ratio is presently 2.7 days.
View Aquestive Therapeutics' Short Interest
.

When is Aquestive Therapeutics' next earnings date?

Aquestive Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for Aquestive Therapeutics
.

How can I listen to Aquestive Therapeutics' earnings call?

Aquestive Therapeutics will be holding an earnings conference call on Wednesday, November 3rd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Aquestive Therapeutics' earnings last quarter?

Aquestive Therapeutics, Inc. (NASDAQ:AQST) issued its quarterly earnings data on Monday, August, 2nd. The company reported ($0.33) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.44) by $0.11. The business earned $15.35 million during the quarter, compared to analyst estimates of $10.63 million.
View Aquestive Therapeutics' earnings history
.

How has Aquestive Therapeutics' stock price been impacted by Coronavirus?

Aquestive Therapeutics' stock was trading at $2.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AQST shares have increased by 49.0% and is now trading at $4.38.
View which stocks have been most impacted by COVID-19
.

What guidance has Aquestive Therapeutics issued on next quarter's earnings?

Aquestive Therapeutics updated its FY 2021 earnings guidance on Tuesday, August, 24th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $46 million-$48 million, compared to the consensus revenue estimate of $40.07 million.

What price target have analysts set for AQST?

3 analysts have issued 1 year price objectives for Aquestive Therapeutics' stock. Their forecasts range from $7.00 to $30.00. On average, they anticipate Aquestive Therapeutics' stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 288.1% from the stock's current price.
View analysts' price targets for Aquestive Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Aquestive Therapeutics' key executives?

Aquestive Therapeutics' management team includes the following people:
  • Keith J. Kendall, President, Chief Executive Officer & Director
  • Daniel Barber, Chief Operating Officer & Senior Vice President
  • A. Ernest Toth, Chief Financial Officer & Senior Vice President
  • A. Mark Schobel, Chief Technology & Innovation Officer
  • Peter Boyd, SVP-Business Process & Information Technology

What other stocks do shareholders of Aquestive Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), Bionano Genomics (BNGO), OrganiGram (OGI), Novan (NOVN), Outlook Therapeutics (OTLK) and KushCo (KSHB).

When did Aquestive Therapeutics IPO?

(AQST) raised $60 million in an initial public offering on Wednesday, July 25th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.

What is Aquestive Therapeutics' stock symbol?

Aquestive Therapeutics trades on the NASDAQ under the ticker symbol "AQST."

How do I buy shares of Aquestive Therapeutics?

Shares of AQST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aquestive Therapeutics' stock price today?

One share of AQST stock can currently be purchased for approximately $4.38.

How much money does Aquestive Therapeutics make?

Aquestive Therapeutics has a market capitalization of $170.32 million and generates $45.85 million in revenue each year. The company earns $-55.78 million in net income (profit) each year or ($1.66) on an earnings per share basis.

How many employees does Aquestive Therapeutics have?

Aquestive Therapeutics employs 187 workers across the globe.

What is Aquestive Therapeutics' official website?

The official website for Aquestive Therapeutics is www.aquestive.com.

Where are Aquestive Therapeutics' headquarters?

Aquestive Therapeutics is headquartered at 30 TECHNOLOGY DRIVE, WARREN NJ, 07059.

How can I contact Aquestive Therapeutics?

Aquestive Therapeutics' mailing address is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. The company can be reached via phone at (908) 941-1900 or via email at [email protected].


This page was last updated on 10/20/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.